Integrated Advisors Network LLC Grows Holdings in Pfizer Inc. (NYSE:PFE)

Integrated Advisors Network LLC grew its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 20.9% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 69,834 shares of the biopharmaceutical company's stock after buying an additional 12,064 shares during the period. Integrated Advisors Network LLC's holdings in Pfizer were worth $1,770,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in PFE. Norges Bank purchased a new position in shares of Pfizer during the 4th quarter worth about $2,328,986,000. Charles Schwab Investment Management Inc. lifted its position in shares of Pfizer by 19.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock worth $4,124,330,000 after purchasing an additional 25,315,159 shares during the period. Starboard Value LP bought a new position in shares of Pfizer during the 4th quarter worth approximately $407,730,000. Raymond James Financial Inc. bought a new position in shares of Pfizer during the 4th quarter worth approximately $274,694,000. Finally, Massachusetts Financial Services Co. MA raised its stake in shares of Pfizer by 7.5% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company's stock worth $2,029,604,000 after acquiring an additional 5,350,381 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

PFE has been the topic of a number of recent analyst reports. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. UBS Group raised their price target on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $25.00 price objective (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Guggenheim reissued a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Finally, Citigroup restated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $29.17.

Pfizer Trading Up 1.5%

Shares of Pfizer stock traded up $0.37 on Thursday, reaching $24.85. The company had a trading volume of 42,445,910 shares, compared to its average volume of 41,112,573. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The firm has a market cap of $141.28 billion, a PE ratio of 17.62, a PEG ratio of 0.64 and a beta of 0.57. The firm's 50 day moving average price is $22.96 and its two-hundred day moving average price is $24.98. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. During the same quarter in the previous year, the business posted $0.82 earnings per share. The business's quarterly revenue was down 7.8% compared to the same quarter last year. Sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 annualized dividend and a dividend yield of 6.92%. Pfizer's dividend payout ratio is presently 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.